Poloxamer 188 prolongs survival of hypotensive resuscitation and decreases vital tissue injury after full resuscitation

Shock

Volumn 32, Issue 4, 2009, Pages 442-450

  Zhang, Rongzhen ^a   Hunter, Robert L ^a,c   Gonzalez, Ernest A ^a   Moore, Frederick A ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c MSB 2136 ^*  (United States)

Author keywords

Drug; Hemorrhagic shock; Rat; Reperfusion injury; Resuscitation; Survival

Indexed keywords

CASPASE; POLOXAMER;

AMPUTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG EFFECT; GERMINAL CENTER; HEART MUSCLE INJURY; HEMORRHAGIC SHOCK; KIDNEY TUBULE NECROSIS; LIVER NECROSIS; MALE; NONHUMAN; PNEUMONIA; RAT; RESUSCITATION; SURVIVAL TIME; TISSUE INJURY;

ANIMALS; HYPOTENSION; MALE; POLOXAMER; RATS; RATS, SPRAGUE-DAWLEY; RESUSCITATION; SHOCK, HEMORRHAGIC; SURFACE-ACTIVE AGENTS;

EID: 70349687544     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31819e13b1     Document Type: Article

References (35)

1. Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, Pons PT: Epidemiology of trauma deaths: a reassessment. J Trauma 38:185-193, 1995.
2. Holcomb JB, Jenkins D, Rhee P, Johannigman J, Mahoney P, Mehta S, Cox ED, Gehrke MJ, Beilman GJ, Schreiber M, et al.: Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 62:307-310, 2007.
3. Handrigan MT, Bentley TB, Oliver JD, Tabaku LS, Burge JR, Atkins JL: Choice of fluid influences outcome in prolonged hypotensive resuscitation after hemorrhage in awake rats. Shock 23:337-343, 2005.
4. Dutton RP, Mackenzie CF, Scalea TM: Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. J Trauma 52:1141-1146, 2002.
5. Dubick MA, Atkins JL: Small-volume fluid resuscitation for the far-forward combat environment: current concepts. J Trauma 54:S43-S45, 2003.
6. Moore FA, McKinley BA, Moore EE: The next generation in shock resuscitation. Lancet 363:1988-1996, 2004.
7. Rushing GD, Britt LD: Reperfusion injury after hemorrhage: a collective review. Ann Surg 247:929-937, 2008.
8. Lee KW, Norell MS: Management of 'no-reflow' complicating reperfusion therapy. Acute Card Care 10:5-14, 2008.
9. Balogh Z, McKinley BA, Cox CS Jr, Allen SJ, Cocanour CS, Kozar RA, Moore EE, Miller IC, Weisbrodt NW, Moore FA: Abdominal compartment syndrome: the cause or effect of postinjury multiple organ failure. Shock 20:483-492, 2003.
10. Grindel JM, Jaworski T, Piraner O, Emanuele RM, Balasubramanian M: Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans. J Pharm Sci 91:1936-1947, 2002.
11. Hymes AC, Safavian MH, Gunther T: The influence of an industrial surfactant Pluronic F-68, in the treatment of hemorrhagic shock. J Surg Res 11:191-197, 1971.
12. Mayer DC, Strada SJ, Hoff C, Hunter RL, Artman M: Effects of poloxamer 188 in a rabbit model of hemorrhagic shock. Ann Clin Lab Sci 24:302-311, 1994.
13. Hickson-Bick DL, Buja ML, McMillin JB: Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J Mol Cell Cardiol 32:511-519, 2000.
14. Fuster V, O'Rourke P, Poole-Wilson P, Walsh R: Pathology of acute myocardial infarction [chapter 57]. In: Hutrst's The Heart. 12th ed. Columbus, OH: McGraw-Hill, 2008.
15. Serbest G, Horwitz J, Barbee K: The effect of poloxamer-188 on neuronal cell recovery from mechanical injury. J Neurotrauma 22:119-132, 2005.
16. Capone AC, Safar P, Stezoski W, Tisherman S, Peitzman AB: Improved outcome with fluid restriction in treatment of uncontrolled hemorrhagic shock. J Am Coll Surg 180:49-56, 1995.
17. Barroso-Aranda J, Schmid-Schonbein GW, Zweifach BW, Engler RL: Granulocytes and no-reflow phenomenon in irreversible hemorrhagic shock. Circ Res 63:437-447, 1988.
18. Eeckhout E, Kern MJ: The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 22:729-739, 2001.
19. Salazar Vazquez BY, Wettstein R, Cabrales P, Tsai AG, Intaglietta M: Microvascular experimental evidence on the relative significance of restoring oxygen carrying capacity vs. blood viscosity in shock resuscitation. Biochim Biophys Acta 1784:1421-1427, 2008.
20. Grover FL, Newman MM, Paton BC: Beneficial effect of Pluronic F-68 on the microcirculation in experimental hemorrhagic shock. Surg Forum 21:30-32, 1970.
21. Hinshaw LB: Sepsis/septic shock: participation of the microcirculation: an abbreviated review. Crit Care Med 24:1072-1078, 1996.
22. Hunter RL, Papadea C, Gallagher CJ, Finlayson DC, Check IJ: Increased whole blood viscosity during coronary artery bypass surgery. Studies to evaluate the effects of soluble fibrin and poloxamer 188. Thromb Haemost 63:6-12, 1990.
23. Knize DM, Weatherley-White RCA, Paton BC: Use of antisludging agents in experimental cold injuries. Surg Gynecol Obstet 129:1019-1026, 1969.
24. Investigators R: Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Collaborative Organization for RheothRx Evaluation (CORE). Circulation 96:192-201, 1997.
25. Orringer EP, Casella JF, Ataga KI, Koshy M, Adams-Graves P, Luchtman- Jones L, Wun T, Watanabe M, Shafer F, Kutlar A, et al.: Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA 286:2099-2106, 2001.
26. Nagata Y, Kakai T, Naike K, Kato R, Fukuta I, Yano T, Kobayashi M: Clinical evaluation on the effect of poloxamer 188 on the hemolysis during cardiopulmonary bypass. J Aichi Med Univ Assoc 11:48-54, 1983.
27. Murhammer DW, Goochee CF: Structural features of nonionic polyglycol polymer molecules responsible for the protective effect in sparged animal cell bioreactors. Biotechnol Prog 6:142-148, 1990.
28. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM: Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 436:1025-1029, 2005.
29. Lee RC, Hannig J, Matthews KL, Myerov A, Chen CT: Pharmaceutical therapies for sealing of permeabilized cell membranes in electrical injuries. Ann N Y Acad Sci 888:266-273, 1999.
30. Justicz AG, Farnsworth WV, Soberman MS, Tuvlin MB, Bonner GD, Hunter RL, Martino-Saltzman D, Sink JD, Austin GE: Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model. Am Heart J 122:671-680, 1991.
31. Williams JH Jr, Chen M, Drew J, Panigan E, Hosseini S: Modulation of rat granulocyte traffic by a surface active agent in vitro and bleomycin injury. Proc Soc Exp Biol Med 188:461-470, 1988.
32. Tan J, Saltzman WM: Influence of synthetic polymers on neutrophil migration in three-dimensional collagen gels. J Biomed Mater Res 46:465-474, 1999.
33. Shakir KM, Williams TJ: Inhibition of phospholipase A2 activity by fluosol, an artificial blood substitute. Prostaglandins 23:919-927, 1982.
34. Ballas SK, Files B, Luchtman-Jones L, Benjamin L, Swerdlow P, Hilliard L, Coates T, Abboud M, Wojtowicz-Praga S, Grindel JM: Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin 28:85-102, 2004.
35. Jordan JR, Moore EE, Sarin EL, Damle SS, Kashuk SB, Silliman CC, Banerjee A: Arachidonic acid in postshock mesenteric lymph induces pulmonary synthesis of leukotriene B4. J Appl Physiol 104:1161-1166, 2008.